S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AMRX Amneal Pharmaceuticals Holding Co

5.87

0.00 (0.00%)

Last Updated: 11:00:00

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/14/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

NIKITA SHAH

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Amneal Pharmaceuticals Charts.

Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Amneal Pharmaceuticals Charts.

Amneal Pharmaceuticals Holding Co News

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
Friday 6 September 2024 (5 months ago) • Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Wednesday 21 August 2024 (5 months ago) • Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Tuesday 20 August 2024 (5 months ago) • Business Wire

Form 144 - Report of proposed sale of securities
Thursday 15 August 2024 (6 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 15 August 2024 (6 months ago) • Edgar (US Regulatory)

UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More
Wednesday 14 August 2024 (6 months ago) • IH Market News

Amneal Reports Second Quarter 2024 Financial Results
Friday 9 August 2024 (6 months ago) • Business Wire

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
Thursday 8 August 2024 (6 months ago) • Business Wire

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
Tuesday 30 July 2024 (6 months ago) • Business Wire

Amneal to Report Second Quarter 2024 Results on August 9, 2024
Friday 12 July 2024 (7 months ago) • Business Wire

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Wednesday 10 July 2024 (7 months ago) • Business Wire

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Monday 1 July 2024 (7 months ago) • Business Wire

More Amneal Pharmaceuticals Holding Co News Articles

BNP Paribas Issuance

BNP Paribas Issuance

BNP Paribas Issuance

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions